Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):306-312. doi: 10.1007/BF03401525. Epub 2017 Nov 30.

PMID:
30091117
2.

An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).

Rizos CV, Athyros V, Bilianou E, Chrousos G, Garoufi A, Kolovou G, Kotsis V, Rallidis L, Skalidis E, Skoumas I, Tziomalos K, Liberopoulos EN.

Hormones (Athens). 2017 Jul;16(3):200-204. doi: 10.14310/horm.2002.1749.

3.

Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.

Rizos CV, Filippatos TD, Elisaf MS.

Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):117-125. doi: 10.1080/17425255.2018.1418325. Epub 2017 Dec 19. Review.

PMID:
29241374
4.

Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.

Filippatos TD, Kei A, Rizos CV, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12. doi: 10.1177/1074248417724868. Epub 2017 Aug 22. Review.

PMID:
28826253
5.

Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.

Filippatos T, Tzavella E, Rizos C, Elisaf M, Liamis G.

Expert Opin Drug Saf. 2017 Oct;16(10):1121-1132. doi: 10.1080/14740338.2017.1361400. Epub 2017 Aug 4. Review.

PMID:
28748724
6.

Gitelman syndrome: an analysis of the underlying pathophysiologic mechanisms of acid-base and electrolyte abnormalities.

Filippatos TD, Rizos CV, Tzavella E, Elisaf MS.

Int Urol Nephrol. 2018 Jan;50(1):91-96. doi: 10.1007/s11255-017-1653-4. Epub 2017 Jul 25. Review.

PMID:
28744758
7.

Severe hyperkalemia following blood transfusions: Is there a link?

Rizos CV, Milionis HJ, Elisaf MS.

World J Nephrol. 2017 Jan 6;6(1):53-56. doi: 10.5527/wjn.v6.i1.53.

8.

L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.

Florentin M, Elisaf MS, Rizos CV, Nikolaou V, Bilianou E, Pitsavos C, Liberopoulos EN.

Lipids. 2017 Jan;52(1):1-9. doi: 10.1007/s11745-016-4216-z. Epub 2016 Dec 2.

PMID:
27914033
9.

Statin myopathy: navigating the maze.

Rizos CV, Elisaf MS.

Curr Med Res Opin. 2017 Feb;33(2):327-329. doi: 10.1080/03007995.2016.1255601. Epub 2016 Nov 11. No abstract available.

PMID:
27805428
10.

Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

Barkas F, Elisaf M, Rizos CV, Klouras E, Kostapanos MS, Liberopoulos E.

Hippokratia. 2015 Oct-Dec;19(4):332-7.

11.

The current role of thiazolidinediones in diabetes management.

Rizos CV, Kei A, Elisaf MS.

Arch Toxicol. 2016 Aug;90(8):1861-81. doi: 10.1007/s00204-016-1737-4. Epub 2016 May 10. Review.

PMID:
27165418
12.

Telmisartan: a multifaceted antihypertension drug.

Rizos CV, Elisaf MS.

Curr Med Res Opin. 2016 Aug;32(8):1397-8. doi: 10.1080/03007995.2016.1176015. Epub 2016 Apr 15. No abstract available.

PMID:
27052942
13.

The effect of rosuvastatin on low-density lipoprotein subfractions in patients with impaired fasting glucose.

Rizos CV, Kostapanos MS, Rizos EC, Tselepis AD, Elisaf MS.

J Cardiovasc Pharmacol Ther. 2015 May;20(3):276-83. doi: 10.1177/1074248414549419. Epub 2014 Sep 18.

PMID:
25237153
14.

Antihypertensive drugs and glucose metabolism.

Rizos CV, Elisaf MS.

World J Cardiol. 2014 Jul 26;6(7):517-30. doi: 10.4330/wjc.v6.i7.517. Review.

15.

Reaching low density lipoprotein cholesterol targets.

Rizos CV, Barkas F, Elisaf MS.

Curr Med Res Opin. 2014 Oct;30(10):1967-9. doi: 10.1185/03007995.2014.941979. Epub 2014 Jul 31.

PMID:
25055191
16.

Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.

Kostapanos MS, Rizos CV, Elisaf MS.

Drug Saf. 2014 Jul;37(7):481-500. doi: 10.1007/s40264-014-0169-4. Review.

PMID:
24788803
17.

Antihypertensive drug therapy in patients with African ancestry.

Rizos CV, Elisaf MS.

Expert Opin Pharmacother. 2014 Jun;15(8):1061-4. doi: 10.1517/14656566.2014.903921. Epub 2014 Apr 3.

PMID:
24697318
18.

Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Agouridis AP, Rizos CV, Elisaf MS, Filippatos TD.

Rev Diabet Stud. 2013 Summer-Fall;10(2-3):171-90. doi: 10.1900/RDS.2013.10.171. Epub 2013 Aug 10. Review.

19.

Combining rosuvastatin with angiotensin-receptor blockers of different PPARĪ³-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.

Rizos CV, Liberopoulos EN, Tellis K, DiNicolantonio JJ, Tselepis AD, Elisaf MS.

Angiology. 2015 Jan;66(1):36-42. doi: 10.1177/0003319713512556. Epub 2013 Nov 27.

PMID:
24288364
20.

An improved algorithm to generate a Wi-Fi fingerprint database for indoor positioning.

Chen L, Li B, Zhao K, Rizos C, Zheng Z.

Sensors (Basel). 2013 Aug 21;13(8):11085-96. doi: 10.3390/s130811085.

Supplemental Content

Support Center